Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Memory Pharmaceuticals, a biopharmaceutical company, has received a new US patent which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists.
Subscribe to our email newsletter
These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer’s disease and cognitive impairment associated with schizophrenia (CIAS).
The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.
Memory Pharmaceuticals is currently conducting a Phase II trial for R3487/MEM 3454 in CIAS. The company recently announced the completion of its Phase I program for R4996/MEM 63908 and that it expects to report the top-line data from that program in the fourth quarter of 2008.
Vaughn Kailian, president and CEO of Memory Pharmaceuticals, said: “This patent provides broad coverage of R3487/MEM 3454 and R4996/MEM 63908, further extends our leadership position in the development of nicotinic alpha-7 receptor agonists, and underscores our commitment to bring forward novel therapies for the treatment of central nervous system disorders. We look forward to continuing to work with our partner Roche to advance our robust development programs for these compounds.”